Loblaw pharmacy sales rise 5.7%, outpacing grocery growth
Novartis shares fell on Nov. 19 after the Swiss drugmaker issued new sales guidance through 2031, and research notes from J.P. Morgan, Jefferies and Vontobel offered different readings of its pipeline and earnings outlook. J.P. Morgan said the guidance likely would lift consensus estimates. Jefferies questioned whether new medicines could replace sales lost to patent expirations after 2030. Vontobel’s Stefan Schneider described a broad pipeline with ample potential and viewed the midterm guidance as positive.
J.P. Morgan analysts said the new guidance was likely to trigger upgrades to consensus expectations for the Swiss drugmaker. Based on the $56.57 billion in sales Novartis was expected to report for 2026, the guidance would imply 2031 sales of $71.11 billion, 2% ahead of consensus estimates. Assuming a 40% core operating profit margin in 2031, core operating profit would come to $28.45 billion, in line with consensus forecasts, the analysts added. Novartis shares fell 2.4%.
Jefferies said Novartis had sought to address concerns about replacing sales lost to patent expirations after 2030, but some long-term commitments relied on products that faced questions. The drugmaker offered better numbers for key in-market drugs without fully improving visibility on medicines still under development, Jefferies said. Novartis shares fell 2.3%.
Jefferies raised specific concerns about two candidates. Its analysts cited neuromuscular medicine del-desiran, whose late-stage study fell short of its main objective. The path for pacibekitug, a candidate for atherosclerotic cardiovascular disease, was also in doubt after a similar rival medicine from Novo Nordisk failed, the analysts said. The efficacy and commercial profiles of earlier-stage assets remained uncertain, they added.
Vontobel’s Schneider said Novartis expected annual sales growth of 5% through 2031 and viewed the new midterm sales guidance as positive. He said breast-cancer drug Kisqali and multiple-sclerosis medicine Kesimpta would face competition from the first generic products in 2031. The note said Novartis raised peak sales expectations for Kesimpta, Scemblix and Leqvio and now saw more than 35 studies on pipeline drugs enabling regulatory submissions through 2031. Novartis shares were down 2.3%.
Loblaw’s pharmacy unit, Shoppers Drug Mart, grew total drug retail sales 5.7% in the third quarter, to C$5.81 billion. That was more than double the 2.8% growth rate of Loblaw’s grocery business.
Shoppers Drug Mart’s same-store sales rose 4.8%, benefiting from specialty and chronic prescriptions. On a same-store basis, the number of prescriptions dispensed in the quarter increased 3.9%, with average prescription value up 4.3%. For Loblaw’s front store, beauty and over-the-counter products were the biggest drivers.
RHB Research said demand for Riverstone Holdings’ cleanroom gloves was strong, pointing to management commentary, and expected that demand to extend into 1Q 2027. Six additional production lines were expected to be fully operational by 1Q 2027, the analysts said, supporting further sales volume growth.
Riverstone was also seeking to expand its non-cleanroom glove consumables business, including face masks and packaging. RHB Research upgraded Riverstone Holdings’ stock to buy from neutral and maintained its target price at 0.90 Singapore dollar, citing valuations that had turned attractive. The shares were 6.3% higher at S$0.76.